ClinicalTrials.gg
TerminatedNCT02536300Updated Aug 14, 2023Results posted

Dose Optimization Study of Idelalisib in Follicular Lymphoma

A Phase 3 interventional study of Idelalisib in Follicular Lymphoma, sponsored by Gilead Sciences. Terminated at 66 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Why this study was terminated
Gilead has made the decision to close the study due to enrollment challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.

Enrollment
4th of 12
96 · median 18
Started
2016
the only one that year
Phase 3
3 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
7 of 12
Gilead Sciences

Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 3, and was the 9th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing idelalisib in Lymphoma, Follicular as a file.
02

Study summary

The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

03

Conditions studied

  • Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed diagnosis of B-cell follicular lymphoma (FL), and grade limited to 1, 2, or 3a based on criteria established by the World Health Organization (WHO) 2008 classification of tumors of hematopoietic and lymphoid tissues
  • FL and have received at least 2 for FL and have no other available therapeutic options. Note: Rituximab maintenance is not routinely considered a separate line of therapy when it is given as part of the prior rituximab-containing regimen given over a number of cycles followed by maintenance. Rituximab monotherapy may be considered a separate line of therapy when disease relapse occurs between the initiation of rituximab monotherapy and the preceding line of therapy. If there are any ambiguities about eligibility, the site should consult with the medical monitor.
  • Ann-Arbor Stage 2 (non-contiguous), 3, or 4 disease per Lugano Classification Radiographically measurable lymphadenopathy or extranodal lymphoid (defined as the presence of ≥ 1 lesion that measures ≥ 1.5 cm in the longest dimension (LD) and ≥ 1.0 cm in the longest perpendicular dimension (LPD) as assessed by positron emission tomography-computed tomography (PET-CT), computed tomography (CT) or magnetic resonance imaging (MRI)
  • Required baseline central laboratory data in protocol.
  • For female individuals of and male individuals of , willingness to use a protocol- recommended method of
  • Lactating females must agree to discontinue nursing
  • Willing and able to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions including mandatory prophylaxis for Pneumocystis jirovecii pneumonia (PJP)

Key Exclusion Criteria:

  • History of lymphoid malignancy other than FL (eg, diffuse large B-cell lymphoma)
  • Known history of, or clinically apparent, central nervous system (CNS) lymphoma or lymphoma.
  • Known presence of intermediate- or high-grade myelodysplastic syndrome.
  • Known history of serious allergic reaction including anaphylaxis or Stevens- Johnson syndrome/ toxic epidermal necrolysis
  • History of a non-lymphoid malignancy except for protocol allowed exceptions
  • Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
  • Known history of drug-induced liver injury, chronic active virus (HBV), chronic active virus (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis
  • History of or ongoing drug-induced pneumonitis
  • History of or ongoing inflammatory bowel disease
  • Known (HIV) infection
  • History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  • Ongoing therapy, including systemic (> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for anemia and/or thrombocytopenia
  • Concurrent participation in another therapeutic clinical trial
  • Prior treatment with phosphatidylinositol 3-kinase (PI3K) inhibitors
  • Cytomegalovirus (CMV): Ongoing infection, treatment, or specifically CMV antiviral prophylaxis within 28 days prior to the screening visits CMV test

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Idelalisib 150 mg BID

    Participants will receive idelalisib 150 mg twice daily continuously. For participants enrolled prior to protocol amendment 5: Based on the independent review committee (IRC) response assessment, participants may be discontinued from the study or may receive blinded or open-label idelalisib 150 mg twice daily.

    Drug: Idelalisib

  • Experimental
    Idelalisib 100 mg BID

    Participants will receive idelalisib 100 mg twice daily continuously. Based on the IRC response assessment, participants may either be dose escalated to open-label 150 mg twice daily or maintain blind and continue on idelalisib 100 mg twice daily. As of protocol amendment 5, enrollment to this arm has been closed.

    Drug: Idelalisib

  • Experimental
    Idelalisib 150 mg BID INT

    Participants will receive idelalisib 150 mg twice daily in 28-day cycles with 21 days on-treatment and 7 days off-treatment.

    Drug: Idelalisib

Interventions

  • Idelalisib tablet administered orally

    Also known as: Zydelig®, GS-1101, CAL-101

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as percentage of participants who achieve a partial response (PR) or complete response (CR). PR criteria: No evidence of new disease, a ≥50% decrease from baseline in sum of products of diameters (SPD) of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. Persistence of bone marrow involvement in a participant who meets other criteria for CR based on the disappearance of all nodal and extra-nodal masses. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in longest dimension (LD) for large nodes and ≤1.0 cm in LD, ≤1.0 cm in longest perpendicular dimension (LPD) for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.

    Time frame: Randomization up to end of treatment (maximum duration: 73.5 months)

  2. Number of Participants With Grade 4 or Higher Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.

    Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)

Secondary outcomes

  1. Duration of Response (DOR)

    DOR: interval from first documentation of CR/PR to earlier of first documentation of disease progression (PD) by independent review committee (IRC)/death from any cause. PR:No evidence of new disease,≥50% decrease from baseline in SPD of index lesions,no increase in non-index disease, no increase in liver/spleen size,no new liver/spleen enlargement; Persistence of bone marrow involvement in participant who meets other CR criteria. CR: No evidence of new disease,regression of all index nodal lesions to normal size (large nodes:≤1.5 cm in LD;small nodes:≤1.0 cm in LD,≤1.0 cm in LPD), regression to normal of all nodal non-index disease,disappearance of all detectable extra-nodal index,non-index disease,normal spleen and liver size, no new liver/spleen enlargement; PD: New node of \>1.5 cm or \>1.0 to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion,new non-index disease,increase by 50% in SPD of index lesions,LD of individual node/extra-nodal mass.

    Time frame: From first documentation of CR or PR until PD or death from any cause (maximum duration: 73.5 months)

  2. Overall Response Rate (ORR) by Week 24

    ORR by Week 24 is defined as the percentage of participants who achieve a PR or CR by Week 24. PR criteria: No evidence of new disease, a 50% decrease from baseline in SPD of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in LD for large nodes and ≤1.0 cm in LD, ≤1.0 cm in LPD for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.

    Time frame: First dose date up to Week 24

  3. Number of Participants With Any TEAE, Grade 3 or Higher TEAEs, Serious TEAEs, Idelalisib-related TEAEs, TEAEs Leading to Interruption or Discontinuation of Idelalisib

    TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants are counted at the highest AE grade experienced.

    Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)

  4. Number of Participants With Clinically Significant Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days. Laboratory abnormalities included hematology and serum chemistry parameters. Clinically significant laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for severity as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening). The number of participants with any post-baseline abnormal laboratory value in Grade 1-4 categories are reported.

    Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)

  5. Time to Onset of Adverse Events of Interest (AEIs)

    Time to onset of AEIs is defined as the interval (in months) from the start of idelalisib treatment to the first documentation of start of AEI. AEIs included grade ≥ 3 diarrhea/colitis, rash, febrile neutropenia, infection, and any grade of: Pneumonitis, bowel perforation, progressive multifocal leukoencephalopathy (PML), Pneumocystis jirovecii pneumonia (PJP), cytomegalovirus (CMV) infection, and organizing pneumonia.

    Time frame: First dose date up to 30 days after last dose of study drug (maximum 64.6 months)

  6. Progression-Free Survival (PFS)

    PFS is defined as the interval (in months) from randomization to the earlier of the first documentation of PD by IRC or death from any cause. PD criteria: New node of \>1.5 cm or \>1.0 cm to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion, new non-index disease, increase by 50% in SPD of index lesions, LD of individual node/extra-nodal mass.

    Time frame: Randomization up to PD or death from any cause (maximum duration: 73.5 months)

  7. Overall Survival (OS)

    OS is defined as the interval (in months) from randomization to death from any cause.

    Time frame: Randomization up to death from any cause (maximum duration: 73.5 months)

  8. Trough Plasma Concentration of Idelalisib

    Time frame: Predose on Day 1, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 32, and 48

  9. Peak Plasma Concentration of Idelalisib

    Time frame: 1.5 hours postdose on Day 1, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 32, and 48

07

Results

Posted Aug 14, 2023

Participant flow

Participants were enrolled at study sites in Australia, Canada, Europe, Israel, and the United Kingdom.

Participant flow — Overall Study
MilestoneIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Started472722
Completed000
Not completed472722
Withdrew: Investigator's discretion17112
Withdrew: Progressive disease1176
Withdrew: Study terminated by sponsor647
Withdrew: Death705
Withdrew: Withdrew consent420
Withdrew: Initiation of non-study specific anti-cancer therapy in the absence of progression121
Withdrew: Enrolled but never treated001
Withdrew: Non-compliance with study drug100
Withdrew: Protocol violation010

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was defined as percentage of participants who achieve a partial response (PR) or complete response (CR). PR criteria: No evidence of new disease, a ≥50% decrease from baseline in sum of products of diameters (SPD) of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. Persistence of bone marrow involvement in a participant who meets other criteria for CR based on the disappearance of all nodal and extra-nodal masses. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in longest dimension (LD) for large nodes and ≤1.0 cm in LD, ≤1.0 cm in longest perpendicular dimension (LPD) for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.

Time frame:
Randomization up to end of treatment (maximum duration: 73.5 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Overall Response Rate (ORR)38.3 (24.5 to 53.6)44.4 (25.5 to 64.7)40.9 (20.7 to 63.6)
PrimaryNumber of Participants With Grade 4 or Higher Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants were counted at the highest AE grade experienced.

Time frame:
First dose date up to 30 days after last dose of study drug (maximum 64.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 4 or Higher Treatment-Emergent Adverse Events (TEAEs)
ParticipantsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Number of Participants With Grade 4 or Higher Treatment-Emergent Adverse Events (TEAEs)15128
SecondaryDuration of Response (DOR)

DOR: interval from first documentation of CR/PR to earlier of first documentation of disease progression (PD) by independent review committee (IRC)/death from any cause. PR:No evidence of new disease,≥50% decrease from baseline in SPD of index lesions,no increase in non-index disease, no increase in liver/spleen size,no new liver/spleen enlargement; Persistence of bone marrow involvement in participant who meets other CR criteria. CR: No evidence of new disease,regression of all index nodal lesions to normal size (large nodes:≤1.5 cm in LD;small nodes:≤1.0 cm in LD,≤1.0 cm in LPD), regression to normal of all nodal non-index disease,disappearance of all detectable extra-nodal index,non-index disease,normal spleen and liver size, no new liver/spleen enlargement; PD: New node of \>1.5 cm or \>1.0 to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion,new non-index disease,increase by 50% in SPD of index lesions,LD of individual node/extra-nodal mass.

Time frame:
From first documentation of CR or PR until PD or death from any cause (maximum duration: 73.5 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Duration of Response (DOR)27.1 (7.7 to NA)18.0 (2.7 to NA)5.7 (0.3 to NA)
SecondaryOverall Response Rate (ORR) by Week 24

ORR by Week 24 is defined as the percentage of participants who achieve a PR or CR by Week 24. PR criteria: No evidence of new disease, a 50% decrease from baseline in SPD of index lesions, no increase in non-index disease, no increase in liver/spleen size and no new liver/spleen enlargement. CR criteria: No evidence of new disease, regression of all index nodal lesions to normal size (≤1.5 cm in LD for large nodes and ≤1.0 cm in LD, ≤1.0 cm in LPD for small nodes), regression to normal of all nodal non-index disease, disappearance of all detectable extra-nodal index and non-index disease, normal spleen and liver size, no new liver/spleen enlargement, morphologically negative bone marrow.

Time frame:
First dose date up to Week 24
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Week 24
percentage of participantsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Overall Response Rate (ORR) by Week 2436.2 (22.7 to 51.5)33.3 (16.5 to 54.0)27.3 (10.7 to 50.2)
SecondaryNumber of Participants With Any TEAE, Grade 3 or Higher TEAEs, Serious TEAEs, Idelalisib-related TEAEs, TEAEs Leading to Interruption or Discontinuation of Idelalisib

TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. TEAEs severity was graded according to the NCI CTCAE version 5.0. Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Fatal. Participants are counted at the highest AE grade experienced.

Time frame:
First dose date up to 30 days after last dose of study drug (maximum 64.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Any TEAE, Grade 3 or Higher TEAEs, Serious TEAEs, Idelalisib-related TEAEs, TEAEs Leading to Interruption or Discontinuation of Idelalisib
ParticipantsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Any TEAE452619
Grade 3 or Higher TEAEs412512
Serious TEAEs311911
Idelalisib-related TEAEs382511
TEAEs Leading to Interruption of Idelalisib32186
TEAEs Leading to Discontinuation of Idelalisib28134
SecondaryNumber of Participants With Clinically Significant Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the date of last study drug dose plus 30 days. Laboratory abnormalities included hematology and serum chemistry parameters. Clinically significant laboratory abnormalities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 for severity as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), or Grade 4 (life threatening). The number of participants with any post-baseline abnormal laboratory value in Grade 1-4 categories are reported.

Time frame:
First dose date up to 30 days after last dose of study drug (maximum 64.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Treatment-Emergent Laboratory Abnormalities
ParticipantsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Hematology: Grade 1752
Hematology: Grade 21275
Hematology: Grade 315115
Hematology: Grade 4632
Serum Chemistry: Grade 1958
Serum Chemistry: Grade 21784
Serum Chemistry: Grade 310116
Serum Chemistry: Grade 4731
SecondaryTime to Onset of Adverse Events of Interest (AEIs)

Time to onset of AEIs is defined as the interval (in months) from the start of idelalisib treatment to the first documentation of start of AEI. AEIs included grade ≥ 3 diarrhea/colitis, rash, febrile neutropenia, infection, and any grade of: Pneumonitis, bowel perforation, progressive multifocal leukoencephalopathy (PML), Pneumocystis jirovecii pneumonia (PJP), cytomegalovirus (CMV) infection, and organizing pneumonia.

Time frame:
First dose date up to 30 days after last dose of study drug (maximum 64.6 months)

No measurements were reported for this outcome.

SecondaryProgression-Free Survival (PFS)

PFS is defined as the interval (in months) from randomization to the earlier of the first documentation of PD by IRC or death from any cause. PD criteria: New node of \>1.5 cm or \>1.0 cm to ≤1.5 cm in LD, \>1.0 cm in LPD, new/unequivocal reappearance of resolved extra-nodal lesion, new non-index disease, increase by 50% in SPD of index lesions, LD of individual node/extra-nodal mass.

Time frame:
Randomization up to PD or death from any cause (maximum duration: 73.5 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Progression-Free Survival (PFS)9.8 (5.5 to 28.7)19.4 (13.9 to 23.3)8.3 (2.9 to 8.7)
SecondaryOverall Survival (OS)

OS is defined as the interval (in months) from randomization to death from any cause.

Time frame:
Randomization up to death from any cause (maximum duration: 73.5 months)
Reported as:
Median · months
Overall Survival (OS)
monthsIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Overall Survival (OS)28.7 (14.0 to NA)NA (23.3 to NA)NA (13.9 to NA)
SecondaryTrough Plasma Concentration of Idelalisib
Time frame:
Predose on Day 1, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 32, and 48
Reported as:
Mean · nanograms per milliliter (ng/ml)
Trough Plasma Concentration of Idelalisib
nanograms per milliliter (ng/ml)Idelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Day 1NA ± NANA ± NANA ± NA
Week 2683.68 ± 514.166382.94 ± 352.842636.35 ± 461.042
Week 4623.64 ± 466.557447.78 ± 356.97194.14 ± 231.647
Week 6581.20 ± 470.988361.90 ± 248.996596.80 ± 401.619
Week 8655.16 ± 498.873430.33 ± 477.87777.66 ± 274.313
Week 10616.05 ± 370.862356.12 ± 372.557387.40 ± 314.249
Week 12630.56 ± 664.066389.21 ± 466.104272.44 ± 626.451
Week 16729.23 ± 832.158730.29 ± 936.798111.67 ± 296.666
Week 20525.91 ± 411.330745.58 ± 841.105107.34 ± 269.434
Week 24460.74 ± 321.766728.76 ± 760.391NA ± NA
Week 32446.13 ± 450.821388.58 ± 351.293352.73 ± 875.923
Week 48706.13 ± 580.022552.13 ± 571.081165.00 ± 368.951
SecondaryPeak Plasma Concentration of Idelalisib
Time frame:
1.5 hours postdose on Day 1, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 32, and 48
Reported as:
Mean · ng/ml
Peak Plasma Concentration of Idelalisib
ng/mlIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
Day 12626.12 ± 1330.2901575.81 ± 803.3172221.35 ± 1621.291
Week 22306.12 ± 810.4331520.29 ± 675.0892186.89 ± 1265.850
Week 42353.95 ± 930.7541528.48 ± 759.9362608.12 ± 1009.937
Week 62433.33 ± 1092.9691682.52 ± 939.4552341.33 ± 948.133
Week 82207.59 ± 980.6061649.25 ± 940.6832786.43 ± 1591.408
Week 102435.00 ± 1027.4691601.11 ± 804.6052380.00 ± 1118.679
Week 122328.13 ± 1141.7641658.89 ± 837.1592316.20 ± 1391.815
Week 162634.39 ± 1323.6111756.37 ± 826.7842372.50 ± 1335.420
Week 202354.26 ± 1440.5871925.29 ± 776.5162177.69 ± 1417.505
Week 242058.47 ± 905.0711914.65 ± 1151.9981906.30 ± 1099.458
Week 322009.71 ± 1231.2962028.00 ± 593.2361825.00 ± 947.892
Week 482655.13 ± 1348.9571448.33 ± 650.7981312.00 ± 850.894

Adverse events

Collected over All-Cause Mortality: Enrollment up to last follow up visit (maximum 73.5 months); Adverse Events: First dose date up to 30 days after last dose of study drug (maximum 64.6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib 150 mg BID20/47 (42.6%)31/47 (66%)44/47 (93.6%)
Idelalisib 100 mg BID12/27 (44.4%)19/27 (70.4%)24/27 (88.9%)
Idelalisib 150 mg BID INT6/22 (27.3%)11/21 (52.4%)16/21 (76.2%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
DiarrhoeaGastrointestinal disorders7/476/270/21
Acute kidney injuryRenal and urinary disorders0/474/270/21
Covid-19Infections and infestations1/471/272/21
Febrile neutropeniaBlood and lymphatic system disorders1/472/270/21
PneumoniaInfections and infestations1/472/271/21
ColitisGastrointestinal disorders3/470/270/21
AnaemiaBlood and lymphatic system disorders2/470/271/21
PyrexiaGeneral disorders1/470/271/21
Abdominal infectionInfections and infestations0/470/271/21
Covid-19 pneumoniaInfections and infestations1/470/271/21
Most frequent other events
Showing 10 of 39
Most frequent other events
EventIdelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INT
DiarrhoeaGastrointestinal disorders19/4712/276/21
NeutropeniaBlood and lymphatic system disorders12/4710/274/21
RashSkin and subcutaneous tissue disorders11/474/276/21
PyrexiaGeneral disorders11/476/273/21
NauseaGastrointestinal disorders5/476/274/21
Aspartate aminotransferase increasedInvestigations8/476/270/21
AnaemiaBlood and lymphatic system disorders10/473/272/21
Alanine aminotransferase increasedInvestigations9/475/270/21
VomitingGastrointestinal disorders4/475/271/21
CoughRespiratory, thoracic and mediastinal disorders8/474/270/21

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Idelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INTTotal
<=18 years0000
Between 18 and 65 years20141145
>=65 years27131050
Age, Continuous
Age, Continuous(years)Idelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INTTotal
Mean65 ± 13.062 ± 13.663 ± 11.664 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INTTotal
Female2313844
Male24141351
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Idelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INTTotal
Hispanic or Latino1023
Not Hispanic or Latino42261785
Unknown or Not Reported4127
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Idelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INTTotal
Race — White42251885
Race — Unknown or Not Reported4127
Race — Asian1001
Race — Black or African American0011
Race — Other or More Than One Race0101
Region of Enrollment
Region of Enrollment(Participants)Idelalisib 150 mg BIDIdelalisib 100 mg BIDIdelalisib 150 mg BID INTTotal
Italy105419
Poland86418
Spain84618
United Kingdom65415
France5229
Czechia4318
Israel4004
Australia0202
Canada1001
Romania1001
08

Study locations

66 sites
  • Calvary Norht Adelaide Hosptial
    Woodville South, South Australia 5011, Australia
  • Royal Victoria Regional Health Centre
    Barrie, L4M 6M2, Canada
  • Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague 10, 10034, Czechia
  • Fakulni newmcince v Motole, Onkologicka klinika 2. LF UK a FN Motol
    Praha 5, 150 06, Czechia
  • Centre Hospitalier d'Avignon-Hopital Henri Duffaut
    Avignon, 84000, France
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, 33077, France
  • Centre Hospitalier Le Mans
    Le Mans, 72037, France
  • Hopital Saint Louis
    Paris Cedex 10, 75475, France
  • Hopital Saint Antoine
    Paris cedex 12, 72012, France
  • Centre Hospitalier Universaitaire de Poit iers-Pole Regional de Cancerlogie
    Poitiers Cedex, 86021, France
  • Centre Hospitalier de Tours-Hopital Bretoneau Centre Regional de Cancerologie Henry Kaplan
    Tours Cedex, 37044, France
  • Clinique Louis Pasteur
    Vandoeuvre-lés-Nancy, 54511, France
  • Carmel Medical Center
    Haifa, 34362, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • ASST Spedali Civili
    Brescia, 25123, Italy
  • Ospedale Policlinico San Martino IRCCS-Clinica Ematologica
    Genoa, 16132, Italy
  • Azienda Policlinico San Martino
    Genova, 16132, Italy
  • Azienda Ospedaliera Cardinale G Panico di Tricase-Unita Operativa Complessa di Ematologia e TMO
    Lecce, 73039, Italy
  • Azienda Ospedaliera Vito Fazzi Unita Operativa di Ematologia
    Lecce, 73100, Italy
  • Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Dipartimento di Oncologia Medica
    Meldola, 47014, Italy
  • IRCCS Ospendale San Raffaele
    Milano, 20132, Italy
  • SCDU Ematologia e Terapie Cellulari Azienda Ospedaliera Ordine Mauriziano di Torino
    Orbassano, 10043, Italy
  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello
    Palermo, 90146, Italy
  • Azienda Unita Sanitaria Locale di Ravenna, U.O di Ematologia
    Ravenna, 48121, Italy
  • Ospedale degli Infermi-Oncoematologia
    Rimini, 47900, Italy
  • Fondazione Policlinico Tor Vergata-UOC Patologie Linfoproliferative
    Rome, 00133, Italy
  • Ospedale S. Eugenio
    Rome, 00144, Italy
  • Dipartimento di Ematologia ed Oncoematolgia - S.C Ematolgia
    Torino, 10126, Italy
  • A.S.U. Integrata Santa Maria della Misericordia
    Udine, 33100, Italy
  • Szpitale Wojewodzkie w Gdyni Sp. z o.o.
    Gdynia, 81-519, Poland
  • PRATIA Onkologia Katowice
    Katowice, 40-519, Poland
  • Malopolskie Centrum Medyczne
    Kraków, 30-510, Poland
  • Wojewodzki Szpital Specjalistyczny w Legniicy
    Legnica, 59-220, Poland
  • Gabinety Lekarskie Hema
    Lublin, 20-090, Poland
  • Szpital Wojewodzki w Opolu Sp. z o.o.
    Opole, 45-372, Poland
  • Instytut Hematologii i Transfuzjologii, Klinika Hematologii
    Warszawa, 02-776, Poland
  • Centrum Onkologii Instytut im.Marii Sklodowskiej Curie
    Warszawa, 02-781, Poland
  • Klinika Hematologii Nowotworow Kriwi i Transplantacji Szpiku
    Wroclaw, 50-367, Poland
  • Spitalul Judetean de Urgenta "Dr. Constantin Opris" Baia Mare
    Baia Mare, 430031, Romania
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Hospital Universitario de Burgos
    Burgos, 09006, Spain
  • Hospital San Pedro de Alcantara
    Cáceres, 10003, Spain
  • Institut Catala d'Oncologia Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, 08908, Spain
  • Hospital General Universiario Gregorio Maranon
    Madrid, 28009, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Centro Integral Oncologico Clara Campal (CIOCC)
    Madrid, 28050, Spain
  • Hospital Puerta de Hierro Majadahonda
    Majadahonda, 28222, Spain
  • Hospital Genereal Universitario Morales Meseguer
    Murcia, 30008, Spain
  • Hospital Son Llatzer
    Palma de Mallorca, 07198, Spain
  • Hospital Universitario de Canarias
    Santa Cruz de Tenerife, 38320, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital Universitario Mutua Terrassa
    Terrassa, 08221, Spain
  • CEIm-Regional De La Comunidad De Madrid
    Valencia, 46026, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
  • East Kent Hospitals University NHS Foundation Trust
    Canterbury, CT1 3NG, United Kingdom
  • London North West University Healthcare NHS Trust
    Harrow, HA1 3UJ, United Kingdom
  • Clatterbridge Cancer Centre NHS Foundation Trust
    Liverpool, L7 8XP, United Kingdom
  • Barts Health Trust
    London, EC1A7BE, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, NW1 2PG, United Kingdom
  • St George's Hospital NHS Trust
    London, SW17 0QT, United Kingdom
  • The Pennine Acute Hospital NHS Trust
    Oldham, OL1 2JH, United Kingdom
  • Torbay and South Devon NHS Foundation Trust
    Torquay, TQ2 7AA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Sep 2022, 80 months.

Results were first posted in Aug 2023, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2015
First posted
Aug 31, 2015
StartActual
Jan 14, 2016
Primary completionActual
Sep 27, 2022
CompletionActual
Sep 27, 2022
Results first posted
Aug 14, 2023
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02536300
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 31, 2015
Start date
Jan 14, 2016
Primary completion
Sep 27, 2022
Completion
Sep 27, 2022
Results posted
Aug 14, 2023
Last update
Aug 14, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion